11-9-2020Cross-posted from NIAID NewsroomLong-Acting Regimen More Effective than Daily Oral Pill Among African WomenA pre-exposure prophylaxis (PrEP) regimen containing …
7-24-2020Cross-posted from NIAID NewsroomNIAID Celebrates Pivotal Step Toward Expanding HIV Prevention Choices for WomenToday the European Medicines Agency (EMA) announc…
7-10-2020As the 23rd International AIDS Conference (AIDS 2020: Virtual) drew to a close yesterday, HIV.gov shared a final interview with Carl Dieffenbach, Ph.D., directo…
7-9-2020Presentations and discussions about the latest HIV research continued at the 23rd International AIDS Conference (AIDS 2020: Virtual) yesterday. HIV.gov shared a…
4-28-2020HRSA’s HIV/AIDS Bureau recently announced five Notices of Funding Opportunity (NOFOs) for initiatives on HIV stigma reduction, implementing rapid ART initiati…
3-31-2020In a period of so many losses, we are now mourning the passing of long-time HIV advocate Barbara Joseph, a Texas native who fought tenaciously for improved serv…
3-11-2020Cross-posted from NIAID NewsroomDolutegravir-containing regimen exhibited superior safety profile in large, NIH-supported study of pregnant women.The antiretrov…
3-9-2020Cross-posted from NIAID NewsroomAmong African adolescent girls and young women who took HIV pre-exposure prophylaxis (PrEP) daily, levels of the PrEP drug tenof…
3-6-2020Cross-posted from TargetHIVNote: On March 10, we will observe National Women and Girls HIV/AIDS Awareness Day. The theme this year is HIV Prevention Starts with…
2-13-2020Cross-posted from NIAID NewsroomThe first clinical trial specifically designed to test the safety of the monthly dapivirine vaginal ring in pregnant women has …
